Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. He is co-founder of a number of biotech companies and is an active board member in several of Aglaia’s portfolio companies. He held several positions with NDDO Oncology BV with respect to oncology drug development strategies. Mark was Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection. As Chief Scientific Officer (CSO) in Oncode Accelerator, Mark will primarily oversee the scientific quality of demonstrator projects.

Oncode Accelerator

Oncode Accelerator is a public-private program which aims to innovate and accelerate the development of new cancer therapies by placing cancer patients at the core of preclinical therapy development.

We realize this through the power of three innovation platforms: Patient Cohorts, Organoids and Artificial Intelligence.

Over 30 partners leverage the full potential of the Dutch innovation ecosystem by building development pipelines for four of the most common types of cancer therapies: Small Molecules, Biologics, Cell and Gene Therapies, and Therapeutic Vaccines.

Our world-class toolbox of state-of-the-art technologies will result in more effective, personalized cancer therapies. This will bring us closer to our overarching vision: outsmarting cancer, impacting lives.

At Innovation for Health, we will announce the opening of our first call and are actively looking for partners in biotech and pharma that can bring lead candidates into our pre-clinical program.